Platelet Aggregation Devices Market
Platelet Aggregation Devices Market - Global Industry Assessment & Forecast
- By Product Systems, Reagents, Consumables and Accessories
- By Application Clinical Applications, Research Applications
- By End User Hospitals, Diagnostic Laboratories, Other End Users
- By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
|Forecast Years:||2022 - 2028|
|Historical Years:||2016 - 2021|
|Revenue 2021:||USD 501.1 Million|
|Revenue 2028:||USD 725.8 Million|
|Revenue CAGR (2022 - 2028):||6.5%|
|Fastest Growing Region (2022 - 2028)||Asia Pacific|
|Largest Region (2021):||North America|
- Cross-segment Market Size and Analysis for Mentioned Segments
- Additional Company Profiles (Upto 5 With No Cost)
- Additional Countries (Apart From Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request Customization Speak To Analyst
Platelet Aggregation Devices Market: By Source, End-User, Application and Region
Global Platelet Aggregation Devices market is valued at USD 501.1 Million in 2021 and is projected to attain a value of USD 725.8 Million by 2028 at a CAGR of 6.5% during the forecast period, 2022–2028. The global market is being fueled by factors such as increased incidences of target diseases, rapid growth in the geriatric population around the world, technological improvements in Platelet Aggregation Devices, and an increasing number of industry-academia collaborations and clinical research. Procedures limits, adverse healthcare changes in the United States, and a scarcity of well-trained and qualified workers are some of the major reasons limiting the market's growth.
Platelet Aggregation Devices Market Size, 2021 To 2028 (USD Million)
The worldwide outbreak of COVID-19 is also likely to benefit the market, and there is significant evidence that SARS-CoV-2 infection is linked to atherothrombotic events. According to the National Clinical Trial Registry (NCT), roughly three clinical trials are now underway to investigate the effect of COVID-19 on Platelet Aggregation Devices, which is predicted to fuel the Platelet Aggregation Devices devices market in the coming years. Platelet Aggregation Devices is used to treat a variety of cardiovascular and bleeding illnesses, but the COVID-19 pandemic is predicted to have an impact on disease treatment as well as the device supply chain around the world.
Increasing Incidences of Cardiovascular Disease
Heart disorders, such as stroke and coronary heart disease, are becoming more common, resulting in a global burden of cardiac mortality, which has fueled the rise of the platelet aggregation devices market. Cardiovascular disease, for example, is mentioned as the underlying cause of mortality in the American Heart Association Research Report 2018, accounting for almost 836,546 deaths in the United States. This equates to approximately one in every three deaths in the country. Every day, around 2,300 Americans die from cardiovascular disease, which equates to one fatality every 38 seconds. The large rise in the number of people suffering from cardiovascular diseases will inevitably raise the use of platelet aggregation devices to study platelet aggregation around the world, and this may push up the price of platelet aggregation devices.
Scarcity of Well-Trained and Qualified Workers
Despite technological advancements and product development over the last decade, the market has been hampered by a shortage of skilled workers who can operate sophisticated instruments like flow cytometers and multi-mode readers. Flow cytometers and spectrophotometers, which are technologically modern and very complicated, produce a wide range of data outputs that require skill to analyze and review. There remains, nevertheless, a global demand-supply gap for trained people.
The Platelet Aggregation Devices Market Is Segmented By Product (Systems, Reagents, Consumables, And Accessories), Application (Clinical Applications And Research Applications), End User (Hospitals, Diagnostic Laboratories, And Other End Users). Based on region, the Platelet Aggregation Devices market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Below tree is interactive. You can click the nodes to get more information.
North America to Continue Dominating the Platelet Aggregation Devices Market
During the forecast period, North America (especially the United States) is expected to be the fastest expanding region in the worldwide platelet aggregation devices market. Companies involved in the development, manufacture, and distribution of platelet aggregation products are flocking to the North American region. Factors such as an increase in surgical procedures, increased awareness among healthcare professionals (related to the benefits of platelet aggregation testing in disease diagnosis), a large number of patients undergoing cardiovascular surgeries, and an increase in the prevalence of orthopedic, urological, and bleeding disorders are all presenting high-growth opportunities for players in the North American platelet aggregation devices market.
Key players operating in the Platelet Aggregation Devices market are: Bio/Data Corporation (US), Helena Laboratories Corporation (US), WerfenLife (Spain),F.Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany).
The Platelet Aggregation Devices market is segmented as follows:
Regions & Countries Covered
Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST
analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market
attractiveness analysis by segments and North America, company market share analysis, and COVID-19
The Platelet Aggregation Devices market scope can be tabulated as below:
Frequently Asked Question
The global Platelet Aggregation Devices valued at USD 501.1 Million in 2020 and is expected to reach USD 725.8 Million in 2028 growing at a CAGR of 6.5%.
The prominent players in the market are Bio/Data Corporation (US), Helena Laboratories Corporation (US), WerfenLife (Spain),F.Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany)..
The market is project to grow at a CAGR of 6.5% between 2021 and 2028.
The driving factors of the Platelet Aggregation Devices include
- Increasing Incidences of Cardiovascular Disease
North America was the leading regional segment of the Platelet Aggregation Devices in 2020.